To validate the contribution of PDGFRβ in acquired resistance in this setting, we pre-treated breast cancer cells with triple combination therapy for 72 h, washed out the inhibitors and further stimulated cells with PDGF-BB ligands for a further 48 h. The gene discussed is CFB; the disease is breast cancer.